Har du en fråga?

Ring oss på
020-79 77 55 (avgiftsfritt).

EXOGEN® Nyheter

NTAC Releases Adoption Pack to Assist Implementation of NICE Guidelines Supporting the Use of EXOGEN

HOOFDDORP, THE NETHERLANDS, 5/13/2013

The NHS Technology Adoption Centre (NTAC), the implementation arm of the National Institute for Health and Care Excellence (NICE), recently launched a new Adoption Pack regarding the EXOGEN Ultrasound Bone Healing System.

The NHS Technology Adoption Centre (NTAC), the implementation arm of the National Institute for Health and Care Excellence (NICE), recently launched a new Adoption Pack regarding the EXOGEN Ultrasound Bone Healing System.

The new adoption pack is designed to help NHS Trusts correctly implement guidelines NICE released (guidance MTG12) supporting the use of EXOGEN as an alternative to surgery for thousands of patients with long bone non-union fractures. The pack includes information about the benefits of EXOGEN to patients/physicians/healthcare systems, the national and local opportunities available, the drivers for adoption, detailed case studies of where EXOGEN has already been successfully used in the NHS, and the costs and potential savings.

NTAC’s experience of working with NHS clinicians, managers and commissioners ensures the information and advice contained within the Adoption Pack is accurate and useful for the NHS.

EXOGEN, which is manufactured and distributed worldwide by Bioventus LLC, uses a unique low-intensity pulsed ultrasound signal to stimulate broken bones to heal naturally, in comparison to surgical management. Patients using EXOGEN place an ultrasound probe on the skin for 20 minutes a day and the treatment, done at home, is entirely pain free with no known side effects. Clinical studies have shown EXOGEN to have an equivalent 86% success rate as surgery4.

The device is used by physicians around the world including many of the UK’s leading surgeons, a number of which have been interviewed for the Adoption Pack. One of these is Angus MacLean, Senior Orthopaedic Consultant at Glasgow Royal Infirmary, who said: “By accelerating health there is significant potential for this technology to save money for the NHS by reducing the need for surgery and returning patients to work more quickly than before. Cost savings and clinical effectiveness therefore make a potential ‘win-win’ situation for the NHS and the patient.”

The full implementation pack can be downloaded at the NTAC website.

Bioventus Announces European Launch of Next Generation EXOGEN Device

HOOFDDORP, THE NETHERLANDS, 7/4/2013

Bioventus, a global leader in active orthopaedic healing, today unveiled the next generation of its market-leading25 EXOGEN Ultrasound Bone Healing System. The new EXOGEN has begun shipping in Europe and will be released in the United States, Canada and Australia later this year.

Bioventus, a global leader in active orthopaedic healing, today unveiled the next generation of its market-leading25 EXOGEN Ultrasound Bone Healing System. The new EXOGEN has begun shipping in Europe and will be released in the United States, Canada and Australia later this year.

EXOGEN – the clinically proven treatment for indicated* bone fractures – is a medical device that helps fractured bones heal. The device:

  • uses safe, effective low-intensity pulsed ultrasound to help stimulate the body’s natural healing process1
  • has an 86% heal rate for fractures not healing on their own4
  • offers 38% faster healing of indicated fresh fractures2,3
  • received guidance from the UK’s National Institute for Health and Care Excellence (NICE) supporting the use of the cost-effective device (guidance MTG12) as an alternative to surgery for nonunions

The new version of EXOGEN introduces new compliance capabilities – such as a log and patient treatment history – to help physicians ensure that patients are appropriately using and benefiting from the device.

“The value of EXOGEN and how it helps fracture patients has long been known and documented,” explained Duncan Fatkin, Vice President of Global Marketing and Reimbursement for Bioventus. “However, patients may not see results unless they adhere to their physician’s prescribed treatment regimen. That’s a theme we heard over and over again as we partnered with physicians, payers and patients to develop the next generation EXOGEN. Achieving better healing outcomes for patients was something they asked us to focus on, and our new features including the reminder calendar address this.”

"The acceleration and promotion of bone healing continues to be an important goal in the treatment of fractures, non-unions and limb reconstruction. Research continues but progress is slow and demanding,” said Gavin De Kiewiet, Director of Trauma for Limb Reconstruction for Sunderland Royal Hospital in the UK. “The EXOGEN device with low-intensity pulsed 

ultrasound has greatly contributed to our ability to help these patients. Backed by sound basic science research, level 1 studies and published successful treatment trials, EXOGEN has significantly enhanced treatment modalities available to all clinicians. Patient friendly, doctor successful, and importantly today, cost effective, it is a treatment that has significantly aided our treatment of fractures and non-unions." 

Prescribed by thousands of physicians around the world, EXOGEN is a portable, lightweight device that features an ultrasound probe that patients place on their skin at the site of the bone break for 20 minutes a day. Patients can easily perform the treatment at home, and EXOGEN has no known contraindications.

The new EXOGEN replaces the previous models available in Europe – EXOGEN 4000+ and EXOGEN Express. The new device is more portable and user friendly, with its new color LCD screen, splash-proof casing, and sleeker, lightweight design; more environmentally friendly, with its removable, rechargeable battery; and more adaptable with an SD card that determines the number of treatments for the device. 

  • Hög
    behandlingsföljsamhet21
  • +
  • Bevisad klinisk
    effektivitet2-4
  • > >
  • Frakturer
    som läker